borderline significantp = 0.05
Excluding this study reduced I 2 to 0% in the desloratadine subgroup, where the effect became borderline significant ( p = 0.05; MD 5.04, 95% CI –0.05 to 10.12), and yielded a significant overall benefit in favor of the combination therapy with low heterogeneity ( p = 0.005; MD 6.71, 95% CI 2.03 to 11.39; I 2 = 12%).